Drug can diminish the symptoms and burden of myelofibrosis

Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase 3 clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of people and alleviated debilitating side effects in more than 46 percent. Ruben A. Mesa, M.D., the study's lead investigator, comments on the findings.

Related Videos